The sale of the cancer-related patent portfolio by Enveric Biosciences represents a strategic shift towards focusing on mental health treatments, which could be seen positively by investors interested in the growing mental health market. This move could potentially increase investor confidence in ENVB's commitment to developing its neuroplastogen candidates, EB-003 and EB-002, aimed at treating depression, anxiety, and addiction disorders. The financial details of the sale were not disclosed, but the transaction is expected to provide necessary funding for the company's focused investment in its mental health treatment pipeline, which could have a positive short-term impact on ENVB's stock price.